YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Radiology, Nuclear Medicine And Imaging

Metastatic Breast Cancer

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.3034